rss
Br J Ophthalmol 2008;92:1456-1460 doi:10.1136/bjo.2008.138867
  • Original Article
    • Clinical science

Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP): 12-month experience with telemedicine screening

  1. Y Murakami,
  2. A Jain,
  3. R A Silva,
  4. E M Lad,
  5. J Gandhi,
  6. D M Moshfeghi
  1. Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA
  1. Dr D M Moshfeghi, Stanford University, 1225 Crane Street, Suite 202, Menlo Park, CA 94025, USA; dariusm{at}stanford.edu
  • Accepted 29 July 2008
  • Published Online First 14 August 2008

Abstract

Background/aims: To report the 1-year experience of the Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP) telemedicine initiative.

Methods: Forty-two consecutively enrolled infants who met ROP examination criteria were screened between 1 December 2005 through 30 November 2006 with the RetCam II and evaluated by the SUNDROP reading centre at Stanford University. Nurses obtained five images in each eye. All patients also received a dilated examination by the author within 1 week of discharge from the hospital. Outcomes included referral-warranted disease, need for treatment and anatomical outcomes. Referral-warranted disease was defined as any Early Treatment Retinopathy of Prematurity (ROP) Disease Type 2 or greater, or any plus disease. A retrospective analysis of 84 eyes, 131 unique examinations and 1315 unique images from the SUNDROP archival data is reported here.

Results: In the initial 12-month period, the SUNDROP telemedicine screening initiative had not missed any referral warranted ROP. Calculated sensitivity and specificity was 100% and 95%, respectively. No patient progressed to retinal detachment or other adverse outcomes.

Conclusions: The SUNDROP telemedicine screening initiative for ROP has proven to have a high degree of sensitivity and specificity for identification of referral warranted disease. These results indicate that telemedicine may improve accessibility of ROP screening.

Footnotes

  • Funding: DMM serves on the Scientific Advisory Board for Clarity Medical Systems (Pleasanton, CA), the manufacturer of the RetCam, RetCam II and Shuttle cameras.

  • Competing interests: None.

  • Ethics approval: Institutional review board approval was obtained from Stanford University Medical Center.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2008.138867v1
    2. bjo.2008.138867v2
    3. 92/11/1456 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.